Organigram Holdings Inc. (TSE:OGI – Free Report) – Analysts at Alliance Global Partners lowered their Q4 2024 earnings estimates for shares of Organigram in a report released on Monday, December 9th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($0.03) for the quarter, down from their prior forecast of ($0.02). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram’s Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.
Separately, Canaccord Genuity Group cut their price objective on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a report on Monday.
Organigram Trading Down 0.5 %
Shares of OGI opened at C$2.16 on Wednesday. The stock’s fifty day simple moving average is C$2.29 and its 200 day simple moving average is C$2.31. Organigram has a twelve month low of C$1.61 and a twelve month high of C$3.95. The company has a current ratio of 6.95, a quick ratio of 2.62 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of C$234.51 million, a P/E ratio of -0.86, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13.
Insiders Place Their Bets
In related news, Senior Officer Paolo De Luca sold 12,014 shares of Organigram stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. 31.32% of the stock is currently owned by insiders.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Recommended Stories
- Five stocks we like better than Organigram
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- The Great CPU Race: AMD and Intel Battle for Dominance
- What is a Dividend King?
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Differences Between Momentum Investing and Long Term Investing
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.